By James Smith, Sunil Arora, Kirsty Morrison and Elisabetta Faenza. In recent years, it has been increasingly challenging for businesses to know what exact process they should follow to be allowed to develop a cannabis medicine. However, the MHRA has recently published an article, which clarifies the current process, entitled: ‘Manufacturing Authorisations or API Registrations […]
Read More
By Dr. Gary Yates, Chair, CIC Plant Science Working Group You might say I’m something of a genetics generalist. After an undergrad degree in genetics and a PhD in molecular interactions (in plant, probiotics and pathogens), I decided to focus on photosynthesis and, eventually, cannabis. As it transpires, such a varied background of study has […]
Read More
By Katya Kowalski, Head of Operations, Volteface Despite the legalisation of medical cannabis in 2018, prescribing practices have remained low and relatively contentious within the UK clinical population. In fact less than 1% of clinicians that can prescribe, currently do. There are a variety of reasons for why medical cannabis has remained on the fringes […]
Read More
By Mike Morgan-Giles, CEO, Cannabis Industry Council The challenges of developing extensive clinical trials for cannabis are well known within the industry, but perhaps less so among policy makers, regulators, and even doctors on the periphery. A range of factors contribute to this, including high start-up costs, complex and somewhat illogical regulations, and the need […]
Read More
By MedCan, CIC member If you haven’t heard of MedCan, we’re a producer of medical cannabis in South Africa. Our claim to fame is that we were the first South African company to be granted a licence to export high THC flower. More than commercial success though, we’re focused on running a sustainable business and […]
Read More
Mike Morgan-Giles, CEO, Cannabis Industry Council. The recently published opinion column in the Daily Mail by David Sidwick (‘Cannabis is now as dangerous as heroin and crack. A liberal approach is not progress – it’s madness’) is a scientifically and medically misguided piece of political posturing. Mr Sidwick’s position is broadly that cannabis causes psychosis, […]
Read More
By Alex Thomson, Director of Operations, The Tax Credit Company Innovation requires investment, and businesses are not always aware of the financial assistance available in the form of Research & Development (R&D) tax relief, Capital Allowances and Grants. No matter where your organisation sits in the supply chain, from production, refinement all the way through […]
Read More
CIC Executive Committee member Jamie Bartley leads the Unyte Group, which comprises seven distinct businesses, all inter-linked by Cannabis and Hemp, with expertise in everything from medical to capital to construction. Right now he’s pushing for further investment into the UK’s industrial hemp sector, as well as legislative change, to help spark what he believes […]
Read More
Chartered Psychologist and Head of Research at Drug Science, Dr Anne Katrin Schlag, heads up the Cannabis Industry Council’s Research Working group. For 2022, the main focus of the Research Subgroup is to carry out a Health economic analysis, create condition-specific case studies, research into chemovar profiles in childhood epilepsy, an exploration of real-world evidence […]
Read More
The medical cannabis industry has grown rapidly over the past few years, with even more growth predicted in the coming years as more patients begin to access this treatment. But while the industry continues to grow, one thing that’s been patchy, at best, is patient engagement. Volteface, along with partner Maple Tree, recognised this flaw […]
Read More